Rgenta Therapeutics: A Rising Star in Oral Small Molecule RNA-Targeted Drug Discovery Secures $52M Series A and Partners with Multiple MNCs

Homogenization of new drug targets has become a widely recognized issue, with major pharmaceutical companies willing to invest heavily in novel targets. In recent years, RNA-targeting has emerged as a prominent area of exploration to overcome the druggability limitations of existing targets. Roche’s revolutionary RNA-targeting small-molecule drug, Evrysdi, demonstrated strong momentum in 2022, achieving an 87% year-over-year growth and generating $1.173 billion in revenue for Roche. This success highlights the significant application potential and commercial opportunities of small-molecule RNA-targeting therapies.

MNCs are continuously seeking pipelines with innovative value, and biotech companies specializing in RNA technology are continually emerging in the market. However, some nucleic acid drugs face limitations, including limited tissue selectivity of in vivo delivery systems, significant challenges in manufacturing and quality control, and potential cytotoxicity associated with vectors.

Small-molecule drugs targeting RNA can bind to specific sites in RNA structure or function, thereby highly specifically regulating RNA expression and activity. This novel mechanism of action gives small-molecule RNA-targeting therapeutics broad application prospects, particularly for difficult-to-treat diseases such as cancer, neurodegenerative disorders, and cardiovascular diseases, while also posing greater technical challenges.Rgenta Therapeutics (hereinafter referred to as “Rgenta”) is one of the most prominent startups in this field.Rgenta focuses on developing innovative small-molecule drugs that target RNA. Its integrated discovery platform analyzes large-scale multi-omics data, including human genomics and transcriptomics, to identify regulatory sites in RNA amenable to selective modulation by small molecules. This enables rapid screening of small-molecule drug candidates targeting RNA, thereby modulating downstream protein expression or altering protein function.

This team, composed of world-class computational biologists, chemists, and genomic scientists, has attracted significant attention from the capital markets. It secured $20 million in seed funding and subsequently closed a $52 million Series A financing round last November, led by the AstraZeneca CICC Healthcare Industry Fund. Other institutional investors behind Rgenta include Lilly Asia Ventures, Boehringer Ingelheim Venture Fund, Vivo Capital, Matrix Partners China, and Cathay Capital.Recently, VCBeat interviewed the company’s founder and CEO, Dr. Xi Hualin.

RNA is an attractive therapeutic target; only 1.5% of the genome is ultimately translated into proteins, whereas 70% is transcribed into RNA. However, due to limited information on the spatial structures of intracellular RNA, relatively low structural diversity, and a lack of experience in small-molecule design, it has been difficult to ensure the specificity of drug–target binding. Consequently, targeting RNA with small-molecule drugs has long remained challenging.

Therefore, the discovery of RNA and related targets, as well as structural studies, are top priorities in the development of small-molecule drugs targeting RNA. Current development efforts fall into three categories: directly identifying small molecules that bind to RNA; inhibiting RNA-modifying enzymes; and using small molecules to modulate the interaction between RNA and regulatory proteins. Representative startups have emerged in each of these areas.

Founded in 2020, Rgenta falls into the third category. The company’s unique technology platform leverages extensive genomic data to identify RNA targets that can be selectively modulated by small molecules, and designs small-molecule splicing modulators to regulate interactions between proteins and RNA.

“Multi-omics data, including genomics and transcriptomics, can reveal how RNA is transcribed within cells and identify potential binding sites for RNA and regulatory proteins. Our small molecules act as stabilizers, simultaneously interacting with proteins and binding to RNA,” introduced Dr. Xi Hualin.

Dr. Hua Lin Xi, Founder and CEO of Rgenta Therapeutics

The human body contains tens of thousands of genes, which are differentially expressed across various cell types. Identifying RNA-binding sites for regulatory proteins is akin to “finding a needle in a haystack,” as many interactions are random rather than representing true binding sites. However, with a sufficiently large number of samples, Rgenta has identified numerous RNA sites potentially amenable to small-molecule targeting through specialized algorithms and targeted experimental validation.

“After identifying the target sites selected by these algorithms, we employ a series of experimental methods to validate them. There are numerous technical details involved in the process from screening to validation. Over the past three years, Rgenta has accumulated extensive experience and optimized the entire workflow. The company has established a comprehensive technology platform capable of supporting our diverse research endeavors.”

In addition to target screening itself, the design and optimization of small-molecule libraries represent another major challenge. “RNA regulation is a highly complex process, with each step offering potential opportunities for modulation by small molecules,” said Xi Hualin.

RNA regulation encompasses not only transcriptional and translational control but also the regulation of RNA splicing, modification, and targeting. Furthermore, RNA regulation requires the participation of various molecules, such as transcription factors, modifying enzymes, and RNA degradation factors.

“RNA structures are regular, and small-molecule functional groups are key regulators of RNA. To identify which small-molecule functional groups are more suitable for binding to RNA, we have constructed a unique compound library to increase the probability of discovering RNA-binding small molecules. Optimization of RNA-targeting small molecules also requires specialized assays. Over the past few years, through in-depth exploration and research on several lead optimization projects, we have accumulated extensive experience. This has also been a process of continuous exploration.”

In just a few years, Rgenta has not only established unique capabilities in discovering small-molecule drugs targeting RNA as an emerging player, but also moved swiftly in forging industry partnerships. It is reported that Rgenta is developing multiple drug candidates for oncology and neurological indications and has established collaborations with several multinational pharmaceutical companies. This progress is closely tied to the industrial background of Rgenta’s founding team.

Dr. Hualin Xi, the company’s founder and CEO, brings over 20 years of experience in the pharmaceutical industry. He previously served as Head of Computational Biology and Genomics at multinational pharmaceutical companies such as Pfizer and AbbVie. Dr. Xi has conducted extensive research in the fields of central nervous system disorders, rare diseases, and oncology, and has gained comprehensive experience across all stages of preclinical drug development, including target validation and drug discovery. He also possesses rich experience in team management and leadership. Dr. Travis Wager, Chief Scientific Officer, also has extensive experience in small-molecule drug R&D and has successfully advanced eight candidate drugs into clinical trials. Professor Zhiping Weng from UMass Medical School, a co-founder of the company, has achieved remarkable scientific accomplishments in computational biology, genomics, and RNA regulation.

“There were two reasons for launching our startup. First, we had long been focused on the field of small-molecule drugs targeting RNA, recognizing substantial opportunities and immense potential. Second, the expertise of Professor Weng, Travis, and myself was highly complementary, effectively covering the most critical aspects of small-molecule RNA targeting,” recalled Xi Hualin, reflecting on the company’s founding motivations. “We began our early preparations in 2019, meeting every weekend at Professor Weng’s office to discuss planning.”

The complementary backgrounds of the three founding members constitute one of Rgenta’s significant advantages. On one hand, investment institutions are becoming increasingly “stringent” regarding the origins of biotech innovators: while they expect teams to possess technological barriers, they place even greater emphasis on comprehensive experience in clinical pipeline product development. Many investors have stated that they now “only consider candidates with industry experience” when evaluating projects.

On the other hand, pharmaceutical giants often choose to collaborate with biotech companies to rapidly enter cutting-edge technological fields. Major pharmaceutical companies such as AstraZeneca, Eli Lilly, Amgen, Johnson & Johnson, Novo Nordisk, Novartis, and Takeda have initiated research and development of RNA-targeted therapeutics through mergers and acquisitions or co-development arrangements.As RNA-focused biotech companies garner increasing attention, mastering collaboration with pharmaceutical firms has become essential for these biotechs, and the Rgenta team excels precisely in this area.

“We have witnessed this field evolve from initial neglect to the current state where every major pharmaceutical company is focusing on RNA-targeted therapeutics. Given Rgenta’s pharmaceutical industry background, we have engaged in extensive contact and communication with many large companies, often with them proactively reaching out to us.”

Rgenta’s currently disclosed collaborations include a partnership with Danish pharmaceutical giant Lundbeck for the development of therapies in neurological indications. Lundbeck specializes in central nervous system (CNS) disorders, focusing on treatments for depression, Alzheimer’s disease, Parkinson’s disease, and schizophrenia. Under this agreement, Rgenta will receive up to $10 million in upfront and near-term payments from Lundbeck, as well as potential clinical and commercial milestone payments totaling up to $100 million for initial target-based projects.

“Partnering with Lundbeck of Denmark is a testament to the recognition of our technology platform. As a world-leading pharmaceutical company specializing in neurological drug development, Lundbeck holds strategic significance for the future advancement of our neuroscience projects.”

Xi Hualin believes that collaborating with large corporations is a key strategic pillar for Rgenta’s development. As a platform company, partnering with multinational pharmaceutical giants helps unlock the value of its technology platforms, with each new project serving as “an inspiration for the next target.” “Our investors include those with strong pharmaceutical industry backgrounds, such as the AstraZeneca CICC Healthcare Industry Fund, Lilly Asia Ventures, and the Boehringer Ingelheim Venture Fund, which opens up further opportunities for potential collaborations.”

Although the potential of developing small-molecule drugs targeting RNA has become a consensus, the field as a whole remains in its early stages, with most companies’ pipelines poised to enter clinical trials within one to two years. Last year, Rgenta’s $52 million new financing round was primarily intended to advance its drug pipeline into clinical development.

Xi Hualin stated, “Our projects in the fields of neurology and oncology are both advancing rapidly, with the hope of entering clinical trials in the near future. We have engaged in discussions with leading experts in these two fields, who have expressed strong interest in this novel mechanism.”

Taking the oncology pipeline as an example, one of Rgenta’s development projects focuses on the treatment of acute myeloid leukemia (AML). Although there are numerous players in the field of targeted therapies for hematologic malignancies, their clinical efficacy remains relatively limited to date. Approximately 50% of patients treated with currently available therapies experience relapse within two to three years, and these treatments are effective only in patients with specific subtypes and defined genetic mutations.

“Our targets are more universal, offering a broader range of mechanistic options for patient treatment. Two additional tumor-related targets are also progressing smoothly. It is truly exciting to have achieved the current results within just three years. For the company, this is a critically important and highly exciting period.”

To address the drug resistance and "undruggability" associated with traditional small molecules, PROTAC technology for targeted protein degradation has taken a leading step, with multiple projects now entering clinical development. Following the emergence of PROTAC degradation technology, a variety of companies have entered the field. Currently, Rgenta is also exploring targeted RNA degradation technologies: "In theory, RNA possesses three-dimensional structures; however, our current understanding of RNA structure remains limited. There is now an increasing amount of data supporting the elucidation of RNA structures and their degradation through small-molecule binding."

Currently, the range of targets applicable to PROTACs remains quite limited. Targeted RNA degradation could unlock a vast array of novel targets, potentially paving the way for more revolutionary therapies.

“We aim to build a competitive edge over the next few years and emerge as a leader in this field.” Xi Hualin expressed optimism about the sector’s prospects, stating, “I believe that more novel targets will emerge in the next five years, and the development of RNA-targeting small-molecule drugs will be truly exciting.”